NASDAQ:RCKT

Rocket Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RCKT

*Your capital is at risk

$3.46

+0.110 (+3.28%)

At Close: Jun 22, 2026

Rocket Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 73.28. In total, the insiders bought 7.34M and sold 526.66K RCKT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	73.28
● Buy	7.34M shares
● Sell	526.66K shares
49% Buy Activity Strong Negative Correlation
Sell Signal Low Confidence May 26, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 73.28. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	20 000 Value: $454.4K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	10 000 Value: $108.5K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	20 000 Value: $291.2K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	10 000 Value: $206.1K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	28 910 Value: $379.3K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	27 003 Value: $514.4K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	18 000 Value: $1.12M
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	9 091 Value: $27.3K
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	15 002 Value: $45.0K
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	24 899 Value: $74.7K
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	51 509 Value: $154.5K
May 26, 2026 Buy	Stock Option (Right to Buy) A-Award	Militello John See Remarks	Officer	16 061 Value: $48.2K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	2 000 Value: $47.8K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	18 000 Value: $446.8K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	49 798 Value: $998.0K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	24 545 Value: $736.6K
May 26, 2026 Sell	Stock Option (Right to Buy) D-Return	Militello John See Remarks	Officer	10 000 Value: $187.5K
May 21, 2026 Buy	Common Stock M-Exempt	Shah Gaurav CEO	CEO / President	76 490 Value: $129.3K
May 21, 2026 Sell	Common Stock S-Sale	Shah Gaurav CEO	CEO / President	55 684 Value: $171.8K
May 21, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Shah Gaurav CEO	CEO / President	76 490 Value: $129.3K
May 19, 2026 Sell	Common Stock S-Sale	Shah Gaurav CEO	CEO / President	2 409 Value: $7K
May 19, 2026 Sell	Common Stock S-Sale	Wilson Martin General Counsel	Officer	662 Value: $2K
May 19, 2026 Sell	Common Stock S-Sale	Militello John See Remarks	Officer	384 Value: $1K
May 13, 2026 Sell	Common Stock S-Sale	Wilson Martin General Counsel	Officer	3 361 Value: $12.1K
May 13, 2026 Sell	Common Stock S-Sale	Shah Gaurav CEO	CEO / President	2 728 Value: $10K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ROCKET PHARMACEUTICALS INC

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder ...

Read Full Profile Here